Compare Enovix Corporation (ENVX) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Zimmer Biomet Holdings Inc — how do they compare? Enovix Corporation trades at $4.62 (market cap $1.11B), while Zimmer Biomet Holdings Inc trades at $92.86 (market cap $17.44B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 15.7× Enovix Corporation's market cap, and Zimmer Biomet Holdings Inc pays a 1.07% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals.
| ENVX | ZBH | |
|---|---|---|
Market Cap | $1.11B | $17.44B |
Sector | Technology | Health |
52-Week High | $15.93 | $107.71 |
52-Week Low | $4.84 | $79.58 |
Enterprise Value | $1.13B | $24.49B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX is trading at $4.59, down 9.29% in the last session, with a bearish technical signal. The company shows consistent quarterly earnings beats but remains deeply unprofitable with a -499.64% net income margin. Recent positive developments include the appointment of a former Apple operations leader as COO and progress in commercial battery production for smart eyewear and smartphone markets.
Despite analyst optimism (75% buy ratings, $12.75 consensus target), ENVX faces significant execution risks as it scales production. The stock offers speculative growth potential in advanced battery technology but requires substantial revenue acceleration to justify current valuations amid persistent cash burn and negative profitability.
Zimmer Biomet (ZBH) trades at $92.94, up 2.1% on the day, with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with a 70% gross margin and positive cash flow trends, though net income margin has declined from 13.8% in 2023 to 8.6% in 2025. Recent developments include expansion in Asia Pacific and a planned $1 billion share repurchase, indicating management confidence.
ZBH presents a moderate growth opportunity with a consensus price target of $97.67, offering ~5% upside. Risks include rising debt levels and competitive pressures in medical devices. Analyst sentiment is mixed with 40% buy ratings, but institutional activity and strategic acquisitions support a stable outlook for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
